Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUTIE Study: Aflibercept Versus Placebo on QTc in Docetaxel-treated Cancer Patients
2008-006796-80Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2008
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Non-hematologic malignancy comparing Aflibercept + docetaxel with Placebo + docetaxel (2 arms). Primary endpoint: QTcF interval. Started Dec 2008; status: completed.
02
Drugs
aflibercept
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2008-006796-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006796-80.